Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Net Cash Flow data on file, last reported at -$246.0 million in Q1 2026.

• Quarterly Net Cash Flow fell 436.61% year-over-year to -$246.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.8 million (up 173.28% YoY) and the FY2025 annual result came in at $248.0 million, up 851.52% from the prior year.
• Net Cash Flow slipped to -$246.0 million in Q1 2026 per RARE's latest filing, from $222.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $368.5 million in Q2 2024 and bottomed at -$331.3 million in Q3 2024.
• The 5-year median for Net Cash Flow is $7.7 million (2022), against an average of -$7.1 million.
• Peak annual rise in Net Cash Flow reached 2164.18% in 2024, while the deepest fall reached 1068.89% in 2024.
• Tracing RARE's Net Cash Flow over 5 years: stood at -$260.1 million in 2022, then soared by 153.59% to $139.4 million in 2023, then sank by 81.25% to $26.1 million in 2024, then soared by 749.94% to $222.1 million in 2025, then sank by 210.75% to -$246.0 million in 2026.
• Per Business Quant, the three latest RARE Net Cash Flow figures stand at -$246.0 million (Q1 2026), $222.1 million (Q4 2025), and $25.8 million (Q3 2025).

Peer Comparison